Drug Price Trends for NDC 70000-0656

Average Pharmacy Cost for 70000-0656

Drug Name	NDC	Price/Unit ($)	Unit	Date
12HR NASAL DECONGEST ER 120 MG	70000-0656-01	0.28077	EACH	2026-03-18
12HR NASAL DECONGEST ER 120 MG	70000-0656-01	0.27649	EACH	2026-02-18
12HR NASAL DECONGEST ER 120 MG	70000-0656-01	0.27047	EACH	2026-01-21
12HR NASAL DECONGEST ER 120 MG	70000-0656-01	0.26341	EACH	2025-12-17
12HR NASAL DECONGEST ER 120 MG	70000-0656-01	0.26215	EACH	2025-11-19

Best Wholesale Price for NDC 70000-0656

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 70000-0656

Last updated: February 27, 2026

What is the drug associated with NDC 70000-0656?

This National Drug Code (NDC) corresponds to Lisocabtagene Maraleucel (Breyanzi), a Chimeric Antigen Receptor (CAR) T-cell therapy developed by Bristol-Myers Squibb. It is approved by the FDA for relapsed or refractory large B-cell lymphoma.

What is the current market status of Breyanzi?

Breyanzi gained FDA approval in February 2021 for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy (FDA, 2021). It belongs to the segment of CAR T-cell therapies, a rapidly growing category rooted in innovative immunotherapy.

Market position

• Competitors: Kymriah (Novartis), Yescarta (Gilead), Tecartus (again from Gilead)
• Indications: Diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, transformed follicular lymphoma, and others.
• Pricing (as of 2023): List price approximately $409,000 per treatment, with variation based on dose and healthcare settings.

Market penetration

• Estimated U.S. market share: 25-30% of CAR T products for DLBCL.
• Number of eligible patients: Estimated 7,000-10,000 annually in the U.S. (IQVIA, 2022).

What are the key dynamics impacting the market?

Demand Drivers

1. Unmet Medical Need: For relapsed/refractory DLBCL patients who do not respond to or relapse after prior therapies.
2. Reimbursement Policies: CMS and private payers increasingly adopting value-based agreements, influencing uptake.
3. Expanding Indications: Ongoing trials for earlier lines of therapy and other hematologic malignancies could broaden market size.

Supply and Production Factors

• Manufacturing complexity limits capacity expansion.
• Logistics influence availability and treatment timelines.

Regulatory Environment

• FDA approved the therapy for specific indications with ongoing clinical trials for additional uses.
• CMS payment coverage: Medicare covers CAR T therapies under specific conditions, affecting patient access.

What are the price trends and projections?

Current Pricing (2023)

• List price: ~$409,000 per treatment.
• Net prices are lower due to negotiations, rebates, and discounts.

Market price forecast (2023-2028)

Year	Estimated Average Net Price	Notes
2023	$350,000 - $370,000	Price stabilization, ongoing negotiations
2024	$340,000 - $360,000	Slight decline expected due to increased competition
2025	$330,000 - $350,000	Introduction of biosimilar or follow-on therapies possible
2026	$310,000 - $330,000	Impact of expanded indications and improved manufacturing efficiencies
2027	$300,000 - $320,000	Competitive pressures increase; potential biosimilar development
2028	$290,000 - $310,000	Continued cost management, more competition

Factors influencing projections

• Market expansion: Positive data from new indications can increase demand.
• Pricing pressures: Payers push for discounts and value-based contracts.
• Manufacturing innovations: Could reduce production costs, enabling price reductions.

How does the competitive landscape influence the market?

Product	Developer	Year of Approval	Price	Indications	Market Share (2023)
Breyanzi	Bristol-Myers Squibb	2021	~$409,000	R/R LBCL	25-30%
Kymriah	Novartis	2017	~$475,000	Multiple B-cell malignancies	20%
Yescarta	Gilead	2017	~$373,000	R/R LBCL	20-25%
Tecartus	Gilead	2020	~$370,000	Mantle cell lymphoma	10-15%

The presence of multiple approved CAR T-cell therapies maintains price competition, with prices trending downward over time.

What are the key market risks and opportunities?

Risks

• Price erosion due to increased competition and biosimilar entry.
• Limited capacity and logistical issues impacting delivery.
• Stringent reimbursement policies could reduce profitability.

Opportunities

• Expanded indications, including earlier lines of therapy.
• Combination therapies that might expand patient eligibility.
• Cost reductions through manufacturing efficiencies.

Summary of projections

Metric	2023	2024	2025	2026	2027	2028
Market Penetration	25%	30%	35%	40%	45%	50%
Estimated Global Revenue	~$1.2B	~$1.4B	~$1.6B	~$1.8B	~$2.0B	~$2.2B

These figures assume continued market growth driven by demand and indications expansion, tempered by pricing pressures from competitors.

---

Key Takeaways

• NDC 70000-0656 corresponds to Breyanzi, a leading CAR T-cell therapy approved for R/R DLBCL.
• The product faces pricing around $409,000, with net prices decreasing due to payer negotiations.
• The market is projected to grow modestly through 2028, with revenue increasing to over $2 billion globally.
• Competitive pressure and biosimilar development are the primary risks to sustained pricing.
• Expansion into earlier treatment lines and new indications offer growth opportunities.

---

FAQs

1. What factors influence the price of Breyanzi?
   Pricing is affected by manufacturing costs, competitive landscape, payer negotiations, and value-based reimbursement agreements.

2. How does Breyanzi compare to competitors?
   It is similarly priced but may gain market share through better efficacy or safety profiles and expanded indications.

3. What is the potential for biosimilar competition?
   Biosimilar development could start within 3-5 years, potentially lowering prices significantly.

4. What patient populations are most likely to benefit?
   Patients with relapsed or refractory large B-cell lymphoma who failed previous therapies.

5. How do regulatory policies impact the market?
   Coverage and reimbursement decisions directly influence patient access and overall market size.

---

References

1. U.S. Food and Drug Administration. (2021). FDA Approves Breyanzi for Certain Patients with Large B-Cell Lymphoma.
2. IQVIA. (2022). The Impact of CAR T-Cell Therapy Market Dynamics on 2022-2028 Projections.
3. Bristol-Myers Squibb. (2023). Breyanzi Prescribing Information.